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A novel coronavirus (SARS-CoV-2) has caused a global pandemic with more than 1.1 million confirmed 
cases and 60,000 deaths.1 To reduce the surge of seriously ill patients,2 governments have issued strict 
physical distancing orders for half of the global population.3 These public health measures4 are difficult 
to sustain and have unintended negative consequences for health, well-being, and justice.5 
Development of an effective vaccine is the clearest path to controlling this pandemic, 6 but will take at 
least one year.7  
Vaccine development could be accelerated by conducting controlled human infection (CHI) studies with 
SARS-CoV-2.8 9 The idea is being pursued by some researchers, and hundreds of people are interested in 
participating.10 In CHI studies, a small number of  participants are deliberately exposed to a pathogen to 
study infection and gather preliminary efficacy data on experimental vaccines or treatments. CHI studies 
have a long, complicated history that includes unethical research.11 Yet they have enabled significant 
improvements in clinical and public heath practice, have been conducted safely for many infectious 
diseases, and recently were instrumental in obtaining licensure for two vaccines.12  
Under what conditions would CHI studies with SARS-CoV-2 be ethically acceptable? Building on existing 
ethical analysis13 14 and recent developments in research ethics,15 our international, multidisciplinary 
group of ethicists, CHI researchers, policymakers, and social scientists has been developing a state-of-
the-art ethical framework for CHI studies.16 Based on this framework, members of our group agree that 
the following conditions should be met to conduct SARS-CoV-2 CHI studies ethically (Table 1). However, 
we differ as to whether these conditions are met at the present time, while acknowledging that the 
situation is rapidly evolving. Rather than arguing for or against SARS-CoV-2 CHI studies, we therefore 
provide guidance for research sponsors, communities, participants and the essential independent 
reviewers considering such studies.   
1. Sufficient social value 
Given that SARS-CoV-2 CHI studies would involve major uncertainty and controversy, they should have 
high social value compared to the alternatives. This requires that studies address the most relevant 
scientific questions in rigorously designed and conducted experiments; results are published quickly and 
widely accessible; and data, samples and challenge strains are appropriately shared. 
Crucially, SARS-CoV-2 CHI studies should have the potential to significantly accelerate vaccine or 
treatment development. Timely vaccine development would likely result in faster control of the 
pandemic and reduce the need for, and associated costs of, physical distancing measures. 
Over 50 investigational vaccines and 100 experimental treatments for COVID-19 are currently in 
development.17 Scholars estimate that SARS-CoV-2 CHI studies with previously uninfected participants 
could expedite vaccine development, notably by selecting the most promising candidates.18 To 
accelerate development, regulatory authorities, researchers and research sponsors must collaborate. 
Stakeholders should, for example, standardize data collection and share data for better aggregation 
across studies ? especially if multiple vaccines are tested.19 Stakeholders should also plan how CHI data 
could be used for launching or modifying larger trials.20 This type of coordination is difficult, and was not 
achieved for proposed Zika virus challenge trials in 2015-16.21 Finally, stakeholders should address 
barriers to widespread, equitable access to any proven effective products.22 
  
SARS-CoV-2 CHI studies also have the potential to yield unique scientific insights. While animal models 
for COVID-19 are being developed and validated, CHI studies could illuminate who is infectious, when, 
and how ? which are key, poorly understood parameters for modelling the course of the pandemic and 
improving the response. This information is difficult to collect by observation alone. Vitally, CHI studies 
could identify correlates of protection, clarify disease mechanisms, and study potential disease 
enhancement in previously-infected individuals, which could inform vaccine and treatment 
development, testing and introduction. Depending on who is enrolled, however, CHI study results may 
not generalize to all populations. 
Alternatives include conducting CHI studies with attenuated SARS-CoV-2 strains or related, milder 
coronavirus strains.23 While these alternatives could reduce the risks to participants and study 
personnel, it is unlikely that their results alone would be sufficiently relevant to address the current 
pandemic. Additionally, CHI studies could be conducted with previously-infected participants only, but 
these may be significantly less valuable for developing vaccines and treatments. Finally, standard 
vaccine efficacy studies could be conducted with at-risk populations, such as healthcare and other 
essential workers. These studies would be less ethically complex, but would likely take more time.  
2. Reasonable risk/benefit profile 
For SARS-CoV-2 CHI studies to be ethically permissible, risks to participants, study personnel and third 
parties should be minimized, reasonable in relation to the social value of the research, and below the 
upper limits of acceptable research risk.24 25 There are both scientific uncertainties about SARS-CoV-2 
and moral uncertainties about the upper limits of research risk. These uncertainties warrant a cautious 
approach to evaluating the risks and potential benefits of SARS-CoV-2 CHI studies and will require 
revisiting risk-benefit judgments as new evidence emerges.  
Risk minimization should focus primarily on reducing the risk of serious outcomes. To minimize risks to 
participants, SARS-CoV-2 CHI studies should recruit young people without underlying medical conditions 
who face lower mortality risks from COVID-19.26 27 28 To minimize risks to study personnel, participants 
should be in inpatient isolation, contact with participants reduced to the extent possible, and robust 
personal protective equipment provided. Participants and personnel should also be carefully monitored, 
promptly managed when symptomatic, and be provided any proven effective targeted treatments (if 
any) or offered enrollment into an appropriate clinical trial. To minimize risks to third parties outside the 
research, participants who decide to withdraw should be confined as needed to prevent transmission. 
Advance coordination with public health authorities would facilitate confinement (which might not 
differ significantly from current physical distancing measures). 
Participants might experience benefits from controlled infection and/or vaccination if they become 
immune to SARS-CoV-2. However, the degree and duration of naturally-acquired and vaccine-derived 
immunity needs further study. Moreover, some participants might receive placebo vaccines, and 
investigational vaccines may prove ineffective. Because these potential benefits of participation remain 
speculative, a cautious approach to risk-benefit evaluations requires that they be given limited, if any, 
weight. Insofar as potential direct benefits do not justify the risks to participants, they must be justified 
by the social value of the research, with higher risks requiring higher social value.  
Finally, even when research has high social value and enrolls competent consenting adults, there is 
substantial consensus that risks to participants should not exceed an absolute upper limit. While 
  
regulations and ethics guidance do not clearly delineate this limit,29 commentators have argued that it 
should not exceed a 1% risk of death30 or the risks posed by activities similar to research, such as living 
kidney donation or volunteer emergency assistance.31 32 Some suggest higher risk limits might be 
permissible for research in an emergency.29  
While data about COVID-19 outcomes are still emerging, and current data come from relatively small 
samples with missing data points and are still being vetted, existing population data suggest healthy 20-
44 year-olds could have a mortality risk of up to 0.2%.33 One model that attempts to account for current 
testing limitations and asymptomatic infections estimates adults ages 20-29 have a 0.03% risk of death 
and a 1.1% risk of hospitalizations.34 The mortality risk could be further reduced by limiting eligibility to 
the youngest women and men (e.g. ages 18-25), carefully monitoring and promptly treating participants, 
and adding exclusion criteria as improved knowledge of risk factors emerges.35 A <0.2% mortality risk is 
higher than in most other research or from common seasonal infections (Table 2). However, it falls 
below the upper risk limits proposed for research even under normal circumstances.36 For third parties, 
there is no recognized upper risk limit;14 however, with the above safeguards, these risks could be 
minimized to a very low level.     
3. Context-specific stakeholder engagement 
CHI studies have a checkered history,37 and it can be counterintuitive for the public that researchers 
would infect people with diseases. Because of uncertainty and worries about public trust, SARS-CoV-2 
CHI studies require early public engagement. Such engagement should convey that CHI studies can 
generally be ethically acceptable and highlight the high social value of SARS-CoV-2 studies specifically, 
alongside risk-mitigating measures taken in these studies. Given unprecedented physical distancing 
measures worldwide and the need for robust, yet swift engagement, novel engagement methods may 
be needed. For example, researchers could convene virtual advisory groups and disseminate 
information through social media. Clear channels for engaging communities and the public during and 
after studies would also be needed to mitigate possible mistrust in research and the health system. 
Rapid and robust engagement might be easier to achieve when the communities and the public are 
already familiar with CHI studies.  
4. Suitable site selection 
Selecting suitable sites for SARS-CoV-2 CHI studies requires considering risks to participants, study 
personnel, and third parties; feasibility of recruitment; availability of necessary infrastructure; and 
potential effects on the local pandemic response. Sites should be selected for sound scientific reasons 
and not based on vulnerability or mere convenience.38 For example, CHI studies could be performed in 
locations with high community spread of SARS-CoV-2 in order to facilitate recruitment. Given that 
participants could require testing, medical attention, and treatment, and research personnel would 
require personal protective equipment, sponsors would also need to demonstrate that CHI studies will 
not unduly compete for scarce resources and thereby compromise the local pandemic response. All sites 
should have sufficient capacity to conduct rigorous studies, provide high-quality care to participants, and 
minimize research risks. Sites experienced with conducting CHI studies might be favored to ensure 
studies and engagement efforts can be launched quickly and responsibly. 
 
  
5. Fair participant selection 
Selecting participants fairly for SARS-CoV-2 CHI studies primarily requires considering fair distribution of 
research risks and burdens and generalizability to relevant populations. Because of the uncertainty and 
potential high risk involved, participants who are at relatively low risk and have capacity to give their 
own consent should be selected (i.e., young, healthy and competent adults). Healthcare professionals 
and other essential workers at increased risk of infection might be especially interested in enrolling, so 
as to develop immunity while receiving care in a controlled setting. However, as discussed, long-lasting 
and highly-protective immunity from infection or vaccination in SARS-CoV-2 CHI studies is currently 
uncertain. Moreover, enrolling essential workers during this pandemic could keep them from their jobs. 
In selecting participants, SARS-CoV-2 CHI studies therefore should avoid undue negative impacts on the 
local pandemic response. 
6. Robust informed consent 
Researchers should use enhanced consent procedures to ensure understanding and voluntariness for 
SARS-CoV-2 CHI studies, including engaging approaches to disclosure and testing potential participants 
on key information.39 In this context, key information includes that participants will be deliberately 
infected, the associated risks and burdens, the study ?Ɛ purpose and social value, areas of uncertainty, 
possible restrictions on withdrawal to protect third parties, and that the study has undergone 
independent review. Ongoing informed consent will be especially important as information continues to 
evolve rapidly, for example about longer-term risks. 
7. Proportionate payment 
As SARS-CoV-2 CHI studies require confinement and additional follow-up, participants should be 
compensated for their time. Assuming this compensation reflects a fair minimum wage for unskilled and 
potentially risky labor,40 U.S. participants might receive several thousand dollars in total. While high 
payments or compensation can be controversial, expecting participants to volunteer without 
compensation risks exploiting them.41 Moreover, worries that high payments cloud understanding have 
generally not been supported by data, which instead suggest payment can help draw attention to risk.42 
Incentive payments beyond compensation might not be unnecessary, given the number of people 
already interested in participating in CHI studies. 
CONCLUSION 
If SARS-CoV-2 CHI studies were to advance, several ethical conditions must be met ? but none of these 
are insurmountable. Given the extraordinary nature of the current situation, even for those who harbor 
ethical concerns, our framework supports laying the groundwork for SARS-CoV-2 CHI studies, such as 
developing and registering a challenge strain and engaging stakeholders to maximize the potential 
benefits of SARS-CoV-2 CHI studies. However, before such studies commence, independent ethical 
review ? preferably by a specially convened committee14 ? should be required to determine that a given 
study meets these conditions, maintains ƚŚĞƉƵďůŝĐ ?ƐƚƌƵƐƚŝŶƌĞƐĞĂƌĐŚ ?43 and is likely to help hasten the 
end of this pandemic. 
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TABLE 1: Framework for ethics of challenge studies applied to COVID-19 
 
 
 
Sufficient social value
ͻCHI studies should address relevant, unresolved scientific questions in rigorously designed and conducted 
experiments; results should be published quickly, in open-access; and data, samples and challenge strains should be 
appropriately shared for future research
ͻCoordination among stakeholders required to standardize data collection, ensure regulatory authorities are willing to 
accept data from CHI studies to accelerate licensure
ͻ Valuable scientific questions for COVID-19 pandemic include: (1) identifying correlates of protection, (2) rapidly 
testing efficacy of interventions, (3) selecting the most promising vaccine candidate(s), and (4) improving 
understanding of disease pathogenesis.
Reasonable risk/benefit ratio
ͻEnroll participants ages 18-25 with no comorbidities
ͻMonitor closely and confine participants for at least 14 days
ͻHave personal protective equipment, mechanical ventilation, medical support staff available to minimize risk to 
study personnel and avoid interfering with outbreak response
Appropriate site selection
ͻConsider feasibility of recruitment, risk, availability of infrastructure, potential effects on outbreak response
ͻConduct in region with ongoing transmission and available expertise, but bring in extra resources to protect 
participants and research staff so as not to hamper outbreak response
Fair participant selection
ͻEnroll younger participants (18-25) who are able to give consent and are at relatively low risk of mortality
ͻConsider enrolling essential workers who are likely to be exposed if their participation will not remove them from 
their essential roles when they are needed 
Context-specific stakeholder engagement
ͻMedia and social media strategy to engage wider community in a time of physical distancing
ͻGather community input about concerns through surveys, interviews, or creation of virtual community advisory 
board
Robust informed consent
ͻKey criteria participants shoudl understand: (1) that they will be deliberately infected, (2) the risks and burdens, (3) 
the purpose of the study, and (4) any restrictions on liberty necessary to protect others
ͻDevelop evidence-based, context-specific materials, test participant understanding and require high level of 
understanding for enrollment 
Proportionate payment
ͻParticipants should be compensated for their time and not exploited 
  
 
Table 2: Comparison of mortality risks for otherwise healthy individuals 
 
SARS CoV-2 
for 
healthcare 
workers in 
China43 
SARS CoV-2 
in 
individuals 
18-25 years 
of age43 43  
Challenge 
study with 
SARS-CoV-2 
(assume 
participants 
18-25 years 
of age) 
Influenza 
(data from 
2019)43 
Influenza 
challenge 
study 
Participation 
in phase I 
healthy 
volunteer 
study43 
Malaria 
challenge 
study43 
0.67% 0.003-0.2% <0.2% 0.01% <0.01% 0.003% None 
reported 
 
Highest estimated risk------------------------------------------------------------------------------>Lowest estimated risk 
 
 
